NEW YORK (GenomeWeb) – Startup molecular diagnostics firm Prostate Management Diagnostics announced on Thursday the first close of a Series A financing round that brought in nearly $1.1 million.

The funding will go toward developing and commercializing genomic tests for the diagnosis and prognosis of prostate cancer. The tests are based on research led by Elaine Mardis and Christopher Maher at the Genome Institute at the Washington University School of Medicine in St. Louis. Prostate Management was founded by the non-profit Peter Michael Foundation.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.